The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XV.o

Path: Endogenous lipoid pneumonia (phospholipidosis)

Publications

Nacca N, Bhamidipati CM, Yuhico LS, Pinnamaneni S, Szombathy T

Severe amiodarone induced pulmonary toxicity.

Journal of thoracic disease. 2012;4(6):667-70

Salaün M, Roussel F, Bourg-Heckly G, Vever-Bizet C, Dominique S, Genevois A, Jounieaux V, Zalcman G, Bergot E, Vergnon JM, Thiberville L

In vivo probe-based confocal laser endomicroscopy in amiodarone-related pneumonia.

The European respiratory journal. 2013;42(6):1646-58

Larsen BT, Vaszar LT, Colby TV, Tazelaar HD

Lymphoid hyperplasia and eosinophilic pneumonia as histologic manifestations of amiodarone-induced lung toxicity.

The American journal of surgical pathology. 2012;36(4):509-16

Koschel D, Handzhiev S, Leucht V, Holotiuk O, Fisseler-Eckhoff A, Höffken G

Hypersensitivity pneumonitis associated with the use of temozolomide.

The European respiratory journal. 2009;33(4):931-4

Ruangchira-Urai R, Colby TV, Klein J, Nielsen GP, Kradin RL, Mark EJ

Nodular amiodarone lung disease.

The American journal of surgical pathology. 2008;32(11):1654-60

Wang CW, Colby TV

Histiocytic lesions and proliferations in the lung.

Seminars in diagnostic pathology. 2007;24(3):162-82

Wang T, Charette S, Smith MI

An unintended consequence: fatal amiodarone pulmonary toxicity in an older woman.

Journal of the American Medical Directors Association. 2006;7(8):510-3

Kharabsheh S, Abendroth CS, Kozak M

Fatal pulmonary toxicity occurring within two weeks of initiation of amiodarone.

The American journal of cardiology. 2002;89(7):896-8

Bedrossian CW, Warren CJ, Ohar J, Bhan R

Amiodarone pulmonary toxicity: cytopathology, ultrastructure, and immunocytochemistry.

Annals of diagnostic pathology. 1997;1(1):47-56

Marchlinski FE, Gansler TS, Waxman HL, Josephson ME

Amiodarone pulmonary toxicity.

Annals of internal medicine. 1982;97(6):839-45

Gefter WB, Epstein DM, Pietra GG, Miller WT

Lung disease caused by amiodarone, a new antiarrythmic agent.

Radiology. 1983;147(2):339-44

Adams PC, Gibson GJ, Morley AR, Wright AJ, Corris PA, Reid DS, Campbell RW

Amiodarone pulmonary toxicity: clinical and subclinical features.

The Quarterly journal of medicine. 1986;59(229):449-71

Dake MD, Madison JM, Montgomery CK, Shellito JE, Hinchcliffe WA, Winkler ML, Bainton DF

Electron microscopic demonstration of lysosomal inclusion bodies in lung, liver, lymph nodes, and blood leukocytes of patients with amiodarone pulmonary toxicity.

The American journal of medicine. 1985;78(3):506-12

Ren H, Kuhlman JE, Hruban RH, Fishman EK, Wheeler PS, Hutchins GM

CT-pathology correlation of amiodarone lung.

Journal of computer assisted tomography. 1990;14(5):760-5

Nicolet-Chatelain G, Prevost MC, Escamilla R, Migueres J

Amiodarone-induced pulmonary toxicity. Immunoallergologic tests and bronchoalveolar lavage phospholipid content.

Chest. 1991;99(2):363-9